Your browser doesn't support javascript.
loading
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Galsky, Matthew D; Daneshmand, Siamak; Izadmehr, Sudeh; Gonzalez-Kozlova, Edgar; Chan, Kevin G; Lewis, Sara; Achkar, Bassam El; Dorff, Tanya B; Cetnar, Jeremy Paul; Neil, Brock O; D'Souza, Anishka; Mamtani, Ronac; Kyriakopoulos, Christos; Jun, Tomi; Gogerly-Moragoda, Mahalya; Brody, Rachel; Xie, Hui; Nie, Kai; Kelly, Geoffrey; Horowitz, Amir; Kinoshita, Yayoi; Ellis, Ethan; Nose, Yohei; Ioannou, Giorgio; Cabal, Rafael; Del Valle, Diane M; Haines, G Kenneth; Wang, Li; Mouw, Kent W; Samstein, Robert M; Mehrazin, Reza; Bhardwaj, Nina; Yu, Menggang; Zhao, Qianqian; Kim-Schulze, Seunghee; Sebra, Robert; Zhu, Jun; Gnjatic, Sacha; Sfakianos, John; Pal, Sumanta K.
Afiliação
  • Galsky MD; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. matthew.galsky@mssm.edu.
  • Daneshmand S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. matthew.galsky@mssm.edu.
  • Izadmehr S; Department of Urology, Keck School of Medicine of USC, Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Gonzalez-Kozlova E; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Chan KG; Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Lewis S; Department of Urology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Achkar BE; Department of Radiology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Dorff TB; Department of Radiology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Cetnar JP; Department of Medical Oncology & Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Neil BO; Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR, USA.
  • D'Souza A; Department of Urology, University of Utah, Salt Lake City, UT, USA.
  • Mamtani R; Division of Hematology and Medical Oncology, Keck School of Medicine of USC, Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Kyriakopoulos C; Division of Hematology and Medical Oncology, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA, USA.
  • Jun T; Division of Hematology and Medical Oncology, University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
  • Gogerly-Moragoda M; Genentech, South San Francisco, CA, USA.
  • Brody R; Formerly with the Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Xie H; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Nie K; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Kelly G; Department of Pathology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Horowitz A; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Kinoshita Y; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Ellis E; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Nose Y; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Ioannou G; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Cabal R; Department of Pathology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Del Valle DM; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Haines GK; Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Wang L; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Mouw KW; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Samstein RM; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Mehrazin R; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Bhardwaj N; Department of Pathology, Molecular and Cell-based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Yu M; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Zhao Q; Gene Dx, Stamford, CT, USA.
  • Kim-Schulze S; Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Sebra R; Department of Radiation Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Zhu J; Department of Urology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Gnjatic S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Sfakianos J; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Pal SK; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nat Med ; 29(11): 2825-2834, 2023 Nov.
Article em En | MEDLINE | ID: mdl-37783966
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Cisplatino Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Med Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Cisplatino Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Nat Med Ano de publicação: 2023 Tipo de documento: Article